The trending targeted protein degradation R&D space has seen a new entry with the 6 April launch of Triana Biomedicines, Inc., a US firm focused on novel molecular glues, which has raised $110m in a series A.
The Waltham, MA-headquartered firm said the money would be used to establish a potentially best-in-class, scalable platform to facilitate the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?